MBRX
Moleculin Biotech, Inc.Company Information
- Company Name
- Moleculin Biotech, Inc.
- CIK
- CIK0001659617
- Category
- Non-accelerated filer<br>Smaller reporting company
- Ticker: Exchange
- MBRX: Nasdaq
- Fiscal Year End
- December 31
- Owner Organization
- 03 Life Sciences
- SIC
- 2834
- SIC Description
- Pharmaceutical Preparations
- Ticker
- MBRX
SEC filing data through
Insider Sentiment
- Last purchase
- 2026-08-03
- Last sale
- —
- Shares purchased (TTM)
- 999,999
- Shares sold (TTM)
- 0
Institutional Sentiment
- As of
- 2026-06-30
- Institutional shares owned
- 185,784
- Shares outstanding
- 5,680,717
- Ownership
- 3.27%
Earnings Market Reaction
- Filing date
- 2026-08-13
- Price on filing date
- —
- 1-month reaction
- 24.34%
- 3-month reaction
- …
Balance Sheet
Values in millions ($)| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 | 2023-09-30 | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Trend |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash And Cash Equivalents At Carrying Value | 7 | 10 | 9 | 7 | 8 | 8 | 4 | 9 | 11 | 17 | 24 | 25 | ||||||
Assets Current | ||||||||||||||||||
| Assets Current | 9 | 11 | 10 | 8 | 9 | 9 | 5 | 12 | 14 | 19 | 26 | 28 | ||||||
| Prepaid Expense And Other Assets Current | 1 | 1 | 1 | 1 | 2 | 2 | 1 | 2 | 3 | 2 | 3 | 3 | ||||||
| Intangible Assets Net Including Goodwill | 11 | 11 | 11 | 11 | 11 | 11 | 11 | 11 | 11 | 11 | 11 | 11 | ||||||
| Other Assets Noncurrent | 1 | 1 | 1 | 1 | 1 | - | 0 | - | - | - | - | - | ||||||
| Operating Lease Right Of Use Asset | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 1 | ||||||
| Property Plant And Equipment Net | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Assets | 21 | 23 | 22 | 20 | 22 | 21 | 17 | 23 | 26 | 31 | 38 | 40 | ||||||
| Accounts Payable Current | 4 | 5 | 4 | 2 | 4 | 3 | 2 | 3 | 3 | 2 | 2 | 2 | ||||||
Liabilities Current | ||||||||||||||||||
| Liabilities Current | 9 | 8 | 7 | 6 | 8 | 7 | 5 | 6 | 6 | 5 | 7 | 4 | ||||||
| Accrued Liabilities Current | 5 | 3 | 3 | 4 | 4 | 4 | 3 | 3 | 3 | 3 | 4 | 2 | ||||||
| Operating Lease Liability Noncurrent | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Derivative Liabilities Noncurrent | 0 | 0 | 0 | 41 | 21 | 14 | 0 | 10 | 2 | 3 | 5 | 0 | ||||||
| Liabilities | 10 | 8 | 7 | 47 | 29 | 21 | 6 | 16 | 8 | 9 | 12 | 4 | ||||||
| Preferred Stock Value | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Common Stock Value | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Additional Paid In Capital Common Stock | 238 | 234 | 221 | 195 | 160 | 160 | 184 | 159 | 159 | 158 | 158 | 156 | ||||||
Stockholders Equity | ||||||||||||||||||
| Aoci Before Tax Attributable To Parent | - | - | - | -0 | -0 | -0 | -0 | 0 | -0 | -0 | -0 | -0 | ||||||
| Stockholders Equity | 12 | 15 | 15 | -27 | -0 | 14 | 11 | 17 | 18 | 22 | 26 | 35 | ||||||
| Accumulated Other Comprehensive Income Loss Net Of Tax | -0 | -0 | 0 | - | - | - | -0 | - | - | - | - | - | ||||||
| Retained Earnings Accumulated Deficit | -226 | -219 | -206 | -222 | -167 | -160 | -172 | -151 | -141 | -137 | -132 | -121 | ||||||
| Accumulated Depreciation Depletion And Amortization Property Plant And Equipment | - | - | 1 | - | - | - | 1 | - | - | - | 1 | - | ||||||
| Liabilities And Stockholders Equity | 21 | 23 | 22 | 20 | 22 | 21 | 17 | 23 | 26 | 31 | 38 | 40 | ||||||
| Preferred Stock Par Or Stated Value Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||||
| Preferred Stock Shares Authorized | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | ||||||
| Preferred Stock Shares Issued | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Preferred Stock Shares Outstanding | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Common Stock Par Or Stated Value Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||||
| Common Stock Shares Authorized | 500 | 500 | 500 | 500 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | ||||||
| Common Stock Shares Issued | 7 | 5 | 3 | 2 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Shares Outstanding | 7 | 5 | 3 | 2 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
Select a line item above to chart it.
Recent filings
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
Financial statements beyond 3 years are for subscribers only.
Unlock 17+ years of income statements, balance sheets, and cash flow statements
Start 7-day free trialMoleculin Biotech, Inc. (MBRX) — SEC Financial Statements & Analysis
Moleculin Biotech, Inc. (MBRX) is a pharmaceutical preparations company, incorporated in DE. Moleculin Biotech, Inc. trades on Nasdaq as: MBRX. Moleculin Biotech, Inc. (MBRX)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-08-13. Based on that filing, Moleculin Biotech, Inc. carries a market cap of $15.85M, a P/E ratio of -0.49x, a P/B ratio of 1.37x, an enterprise value of $8.59M, and an EV/EBITDA multiple of -0.30x. On profitability, it posts a Return on Equity (ROE) of -561.58%, a Return on Assets (ROA) of -152.41%, and a Return on Invested Capital (ROIC) of -494.18%. Per share, it reports EPS of $-5.73, free cash flow per share of $-4.46, and a dividend per share of $0.00. Over the trailing year, it posted net income growth of -19.64% year-over-year and EPS growth of -91.21% year-over-year. On the balance sheet, it maintains a current ratio of 0.94x, a quick ratio of 0.78x, working capital of $-590.00K, a debt-to-equity ratio of 0.82x, a debt ratio of 0.45, an interest coverage ratio of -179.35x, free cash flow of $-25.36M (TTM), and net debt of $-7.26M. Figures sourced from SEC EDGAR.
- Market Cap
- $15.85M
- P/E TTM
- -0.49x
- EPS TTM
- $-5.73
- P/B TTM
- 1.37x
- ROE TTM
- -561.58%
- ROA TTM
- -152.41%
- Debt To Equity
- 0.82x
- Free Cash Flow TTM
- $-25.36M
Data as of 2026-06-30 · Source: SEC EDGAR
Frequently Asked Questions
What industry is Moleculin Biotech, Inc. in?
Moleculin Biotech, Inc. (MBRX) operates in the Pharmaceutical Preparations industry.
What exchange does MBRX trade on?
Moleculin Biotech, Inc. (MBRX) trades on the Nasdaq.
Where is Moleculin Biotech, Inc. incorporated?
Moleculin Biotech, Inc. is incorporated in DE.
When was Moleculin Biotech, Inc. (MBRX)'s most recent SEC filing?
Moleculin Biotech, Inc. (MBRX)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-08-13.
What is MBRX's market cap?
Moleculin Biotech, Inc. (MBRX) has a market capitalization of $15.85M as of 2026-06-30.
What is MBRX's EPS (earnings per share)?
Moleculin Biotech, Inc. (MBRX)'s trailing twelve month EPS is $-5.73 as of 2026-06-30.
What is MBRX's ROE (return on equity)?
Moleculin Biotech, Inc. (MBRX)'s trailing twelve month Return on Equity (ROE) is -561.58% as of 2026-06-30.
What is MBRX's ROA (return on assets)?
Moleculin Biotech, Inc. (MBRX)'s trailing twelve month Return on Assets (ROA) is -152.41% as of 2026-06-30.
What is MBRX's ROIC (return on invested capital)?
Moleculin Biotech, Inc. (MBRX)'s trailing twelve month Return on Invested Capital (ROIC) is -494.18% as of 2026-03-31.
What is MBRX's EV/EBITDA?
Moleculin Biotech, Inc. (MBRX)'s trailing twelve month EV/EBITDA is -0.30x as of 2026-06-30.